Skip to content Skip to footer
Search

Loading Results

Listing of biotech companies on Hong Kong and A-share capital markets

October 2021

The Hong Kong market has grown tremendously over the past three years with the launch of Hong Kong Exchange’s new regime to accept pre-revenue biotech companies, new economy companies and companies with weighted voting rights to list in 2018. New economy companies raised over 60% of IPO funds raised on HKEX over the past three years.

Hong Kong has become the first largest fund raising platform for healthcare and biotech companies in the world after the US market with over 30 pre-revenue biotech companies listed under the new Chapter 18A of the Listing Rules. PwC is proud to have 10 clients which have been successfully listed and raised a total of HKD 23.8b. And 25 clients have submitted their applications as at 30 September 2021.

PwC Hong Kong & Mainland China is launching our first Listing Guide for Biotech Companies which highlights the listing framework for listing on HKEX and the Mainland China A-share market.

Contact us

Brian Choi

Brian Choi

Capital Markets and Accounting Advisory Services Leader, PwC China

Tel: +[86] (10) 6533 2068

Edmond Chan

Edmond Chan

Partner, PwC Hong Kong

Tel: +[852] 2289 1128

Pauline Leung

Pauline Leung

Partner, PwC Hong Kong

Tel: +[852] 2289 1809

Xuemei Li

Xuemei Li

Partner, PwC China

Tel: +[86] (10) 6533 2927

Follow us